Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

DKK 2016 | Incorporating monoclonal antibodies in the treatment algorithm of multiple myeloma

Monoclonal antibodies have been recognised for their significant potential for the treatment of multiple myeloma. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from the University of Cologne, Cologne, Germany, reviews the clinical development of elotuzumab, which targets CS1, and daratumumab, which targets CD38.